100 related articles for article (PubMed ID: 3808943)
1. Interferon enhanced natural killer function in Hodgkin's disease.
Levy S; Reins F; Aleksijevic A; Giron C; Oberling F; Mayer S; Lang JM
Nouv Rev Fr Hematol (1978); 1986; 28(5):323-5. PubMed ID: 3808943
[TBL] [Abstract][Full Text] [Related]
2. Surface markers and cytotoxic activity of blood natural killer cells studied at the single cell level in Hodgkin's disease.
Jezewska E; Björkholm M; Giscombe R; Holm G; Tullgren O
Clin Exp Immunol; 1985 Jul; 61(1):96-102. PubMed ID: 4042422
[TBL] [Abstract][Full Text] [Related]
3. Normal natural killer cell activity in Hodgkin's disease patients in remission.
Douer D; Shaked N; Ramot B
Clin Exp Immunol; 1987 Sep; 69(3):660-7. PubMed ID: 3665188
[TBL] [Abstract][Full Text] [Related]
4. Increased number of functionally defective large granular lymphocytes in lymphoma patients.
Muhonen T; Teerenhovi L; Saksela E
Nat Immun Cell Growth Regul; 1987; 6(2):57-64. PubMed ID: 3600676
[TBL] [Abstract][Full Text] [Related]
5. Natural killer activity in spleens and lymph nodes from patients with Hodgkin's disease.
Ruco LP; Procopio A; Uccini S; Marcorelli E; Baroni CD
Cancer Res; 1982 May; 42(5):2063-8. PubMed ID: 6175405
[TBL] [Abstract][Full Text] [Related]
6. Natural killer (NK) activity in patients with Hodgkin's disease before, during and after multiple-agent therapy.
Frydecka I; Kotlarek-Haus S; Kuliszkiewicz-Janus M; Kuliczkowski K
Arch Immunol Ther Exp (Warsz); 1990; 38(5-6):407-14. PubMed ID: 2130805
[TBL] [Abstract][Full Text] [Related]
7. Natural killer activity and NK cytotoxic factors in peripheral blood and lymph node cells from non-Hodgkin's lymphoma patients.
Nadkarni JJ; Mehta BA; Koppikar SB; Soman CS; Shrikhande SS; Advani SH
Neoplasma; 1989; 36(6):701-8. PubMed ID: 2615873
[TBL] [Abstract][Full Text] [Related]
8. Comparative in vivo and in vitro activation of human natural killer cells by two recombinant alpha-interferons differing in antiviral activity.
Edwards BS; Hawkins MJ; Borden EC
Cancer Res; 1984 Jul; 44(7):3135-9. PubMed ID: 6586292
[TBL] [Abstract][Full Text] [Related]
9. Interferon responsiveness of natural killer cells in type I human diabetes.
Negishi K; Gupta S; Chandy KG; Waldeck N; Kershnar A; Buckingham B; Charles MA
Diabetes Res; 1988 Jan; 7(1):49-52. PubMed ID: 3402165
[TBL] [Abstract][Full Text] [Related]
10. [Cytotoxicity of effector cells of the peripheral blood, lymph nodes and spleen in Hodgkin's disease].
Blokhina NG; Bykovskaia SN; Kharabadze MV; Kupriianova TA; Agafonov VA
Biull Eksp Biol Med; 1989 Nov; 108(11):600-3. PubMed ID: 2633827
[TBL] [Abstract][Full Text] [Related]
11. Analysis of natural killer cell cytotoxicity of cancer patients treated with recombinant interferon.
Lotzová E; Savary CA; Quesada JR; Gutterman JU; Hersh EM
J Natl Cancer Inst; 1983 Nov; 71(5):903-10. PubMed ID: 6580490
[TBL] [Abstract][Full Text] [Related]
12. Natural killer cell activity in patients with multiple sclerosis given alpha interferon.
Rice GP; Casali P; Merigan TC; Oldstone MB
Ann Neurol; 1983 Sep; 14(3):333-8. PubMed ID: 6638954
[TBL] [Abstract][Full Text] [Related]
13. [The functional activity and count of the natural killer cells in patients with recently diagnosed diabetes mellitus types I and II].
Salozhin KV; Sura VV; Nasonov EL; Korneeva MN; Smirnova OI
Ter Arkh; 1989; 61(10):104-6. PubMed ID: 2609254
[TBL] [Abstract][Full Text] [Related]
14. Heat shock protein 90 inhibitor BIIB021 (CNF2024) depletes NF-kappaB and sensitizes Hodgkin's lymphoma cells for natural killer cell-mediated cytotoxicity.
Böll B; Eltaib F; Reiners KS; von Tresckow B; Tawadros S; Simhadri VR; Burrows FJ; Lundgren K; Hansen HP; Engert A; von Strandmann EP
Clin Cancer Res; 2009 Aug; 15(16):5108-16. PubMed ID: 19671844
[TBL] [Abstract][Full Text] [Related]
15. Depressed NK cell activity of peripheral blood mononuclear cells in untreated hodgkin's disease: enhancing effect of interferon in vitro.
Levy S; Tempe JL; Aleksijevic A; Giron C; Oberling F; Mayer S; Lang JM
Scand J Haematol; 1984 Oct; 33(4):386-90. PubMed ID: 6209786
[TBL] [Abstract][Full Text] [Related]
16. Depressed natural killer cell activity in acute myocardial infarction.
Klarlund K; Pedersen BK; Theander TG; Andersen V
Clin Exp Immunol; 1987 Oct; 70(1):209-16. PubMed ID: 3500813
[TBL] [Abstract][Full Text] [Related]
17. Natural killer cell activity in tumor-draining lymph nodes: investigations in patients with malignant melanoma and head and neck cancer.
Micksche M; Vinzenz K; Kokoschka EM; Kokoschka R
Nat Immun Cell Growth Regul; 1985; 4(6):315-27. PubMed ID: 4088287
[TBL] [Abstract][Full Text] [Related]
18. Natural killer cells and interferon responses in patients with systemic lupus erythematosus.
Tsokos GC; Rook AH; Djeu JY; Balow JE
Clin Exp Immunol; 1982 Nov; 50(2):239-45. PubMed ID: 6817954
[TBL] [Abstract][Full Text] [Related]
19. [Cytotoxic activity of K-lymphocytes (killer cells) in Hodgkin's disease].
Górska B; Konopka L; Seyfried H; Pawelski S
Pol Tyg Lek; 1980 Aug; 35(33):1249-51. PubMed ID: 7433209
[No Abstract] [Full Text] [Related]
20. Natural cell-mediated cytotoxicity: a micro assay suitable for clinical tests.
Tentori L; Alvino E; Fuggetta MP; D'Atri S; Giganti MG; Caliendo R; Bonmassar E
Chemioterapia; 1985 Dec; 4(6):471-4. PubMed ID: 3868428
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
